巴基斯坦HIV感染儿童接种单剂伤寒结合疫苗后血清学应答的持久性:一项前瞻性队列研究
该前瞻性队列研究纳入巴基斯坦336名6月龄至15岁HIV感染儿童,接种单剂0.5 ml肌内注射Typbar TCV®后随访12个月,评估抗Vi-IgG抗体血清转换率和几何平均滴度。结果显示1年时仅57.7%儿童维持血清转换,6月龄至5岁儿童及重症HIV临床疾病儿童的血清转换率和GMT显著更低。
要点
- HIV感染儿童接种单剂TCV后1年,仅188/326(57.7%)维持血清转换。
- 6月龄至5岁儿童1年血清转换率110/217(50.7%)显著低于5岁以上儿童78/109(71.6%)。
- 非重症HIV临床疾病儿童1年持续血清转换的aOR为10.61(95%CI 1.52, 73.98)。
核心结论
- HIV感染儿童接种单剂TCV后1年血清转换率显著下降,重症或晚期HIV临床疾病儿童及5岁以下儿童下降更显著。
研究设计与样本
- 前瞻性队列研究,2020年11月20日至2021年1月2日纳入336名巴基斯坦6月龄至15岁HIV感染儿童,随访12个月。
- 接种单剂0.5 ml肌内注射Typbar TCV®,于接种前及接种后4-6周、6个月、1年采集血样,用ELISA检测抗Vi-IgG抗体。
主要发现
- 6个月时血清转换率:6月龄至5岁儿童127/216(58.8%)vs 5岁以上儿童81/111(73.0%)。
- 1年时血清转换率:6月龄至5岁儿童110/217(50.7%)vs 5岁以上儿童78/109(71.6%),仅188/326(57.7%)维持血清转换。
- 6个月时GMT(95%CI):6月龄至5岁儿童9.6(7.6, 12.0)vs 5岁以上儿童28.9(20.2, 41.4)。
- 1年时GMT(95%CI):6月龄至5岁儿童6.6(5.4, 8.0)vs 5岁以上儿童23.1(16.4, 32.5)。
- 持续血清转换的比值随时间显著下降(aOR 0.23;95%CI 0.14, 0.40);非重症HIV临床疾病儿童aOR 10.61(95%CI 1.52, 73.98),较大年龄组儿童aOR 7.45(95%CI 1.18, 47.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to assess the longevity of serologic response and seroconversion rates at several time points following TCV vaccination among children living with HIV aged 6 months to 15 years in Pakistan. METHODS: From November 20, 2020, to January 2, 2021; 336 children were enrolled and followed up prospectively for 12 months. Blood samples were collected before the administration of TCV and at 4-6 weeks, 6 months, and 1 year after administration of a single dose (0.5 ml) of intramuscular Typbar TCV®. Samples were analyzed for anti-Vi-IgG antibodies using ELISA. Geometric mean titers (GMTs), seroconversion rates (fourfold rise in anti-Vi-IgG from baseline) were assessed, and factors associated with sustained seroconversion at 1 year were evaluated using generalized linear mixed models. FINDINGS: The seroconversion rates were significantly lower in children aged 6 months to 5 years compared to children > 5 years; (127/216 (58·8%)) versus (81/111 (73·0%)) at 6 months and (110/217 (50·7%)) versus (78/109 (71·6%)) at 1 year, only two-third; 188/326 (57·7%) remained seroconverted at 1 year. The GMTs (95 % CI) were significantly lower in children aged 6 months to 5 years compared to children > 5 years, 9·6 (7·6, 12·0) versus 28·9 (20·2, 41·4) at 6 months, and 6·6 (5·4, 8·0) versus 23·1 (16·4, 32·5) at 1 year time point. The odds of sustained seroconversion significantly decreased with time (adjusted odds ratio (aOR): 0.23; 95 % CI: 0.14, 0.40). The odds of sustained seroconversion following 1 year of TCV vaccination were significantly higher among children with non-severe HIV clinical disease (aOR: 10·61; 95% CI: 1·52, 73·98) and children in elder age group (aOR: 7·45; 95% CI: 1·18, 47·03). CONCLUSIONS: A significant decrease in seroconversion rates was observed among children living with HIV following one year of TCV administration. The decline was significantly higher in children with severe or advanced HIV clinical disease and children younger than five years of age.
引用
- Batool R, Yousafzai MT, Mir F, et al. Longevity of serologic responses following a single dose of typhoid conjugate vaccine among children living with HIV in Pakistan: A prospective cohort study. Vaccine. 2024. PMID: 38811267. doi:10.1016/j.vaccine.2024.05.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。